Talactoferrin alpha receives fast-track designation for the treatment of non-small cell lung cancer.
McBride
Deborah
D
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D017322:Clinical Trials, Phase II as Topic; D017277:Drug Approval / Q000331:legislation & jurisprudence; D006801:Humans; D007781:Lactoferrin / Q000008:administration & dosage / Q000627:therapeutic use*; D008175:Lung Neoplasms / Q000188:drug therapy*; D010919:Placebos; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D015996:Survival Rate; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D010919:Placebos; D011994:Recombinant Proteins; C515276:talactoferrin alfa; D007781:Lactoferrin